Regeneron Partnering With Ocular May Provide Needed Tech Validation
Executive Summary
Regeneron is partnering with the troubled ophthalmology-focused biotech to develop a sustained-release formulation of Eylea that could enable a less-frequent dosing regimen.
You may also be interested in...
Ocular And UroGen Team-Up With Drug-Makers On Drug-Delivery Hydrogels
Ocular Therapeutix will work with Regeneron to create a sustained-release formulation of aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases. On the same day, UroGen announced plans to work with Allergan on a hydrogel for controlled release delivery of drugs to the bladder.
Deal Watch: Allergan, Regeneron Both Look To Hydrogel Tech
Most of the significant deal-making action during the past week took place in Asia as Piramal made a play to increase its injectables business, an Eisai affiliate out-licensed rights to ovarian cancer candidate farletuzumab, and EpimAb and Kymab agreed to collaborate on bispecific antibody therapeutics.
Ocular Therapeutix's Stock Gets A Shock As Another PhIII Misses Target
Ocular Therapeutix Inc.'s stock plummeted 42% on June 6 after a second Phase III study of its allergic conjunctivitis therapy, Dextenza (sustained-release dexamethasone), failed to reach its single primary endpoint – another big hit for the drug following a Phase III failure in ocular inflammation in 2015.